vestipitant + norethindrone + ethinyl estradiol

GSK189075 + Brevicon is a drug combination studied in clinical pharmacology to evaluate potential drug-drug interactions. It consists of **vestipitant** (GSK189075), a selective neurokinin-1 (NK1) receptor antagonist, and **Brevicon**, a combined oral contraceptive containing the progestin **norethindrone** and the estrogen **ethinyl estradiol**. Vestipitant was developed by GSK for various indications, including chemotherapy-induced nausea and vomiting (CINV), pruritus, and tinnitus, by blocking the binding of substance P to the NK1 receptor. Brevicon acts by suppressing ovulation through the activation of progesterone and estrogen receptors. The combination was specifically utilized in Phase 1 trials to determine if vestipitant, as a potential cytochrome P450 inducer or inhibitor, would alter the pharmacokinetics of the contraceptive steroids, thereby impacting their efficacy.

Other names

vestipitant + BreviconGSK189075 + Brevicon